Colorado 2026 Regular Session

Colorado Senate Bill SB167

Introduced
4/16/26  
Refer
4/16/26  
Report Pass
4/30/26  
Refer
4/30/26  
Report Pass
5/5/26  
Refer
5/5/26  
Engrossed
5/6/26  
Refer
5/6/26  
Report Pass
5/8/26  
Refer
5/8/26  
Engrossed
5/21/26  
Engrossed
5/21/26  

Caption

Prescription Drug Out-of-Pocket Expense Credit

Impact

The law introduces significant implications for both health insurers and covered individuals. It requires insurance providers to integrate direct purchases of prescription drugs into their cost-sharing calculations, potentially lowering the out-of-pocket maximum for many patients. This could encourage more individuals to seek lower-cost alternatives in purchasing medications rather than relying solely on in-network pharmacies, which may have higher pricing structures. This may transform the purchasing dynamics within the healthcare market, promoting the use of more competitive pricing for prescription drugs.

Summary

Senate Bill 167, known as the 'Making Health Care More Affordable Through Prescription Drug Purchases Act', focuses on adjustments to how out-of-pocket expenses attributed to prescription drug purchases are calculated for covered individuals under health benefit plans in Colorado. The bill mandates that starting January 1, 2028, health carriers must account for and credit these expenses towards a covered person’s out-of-pocket maximum or cost-sharing requirements. This change is aimed at reducing the financial burden on individuals who make direct purchases of medications, which have been rising in cost.

Contention

Despite its clear intention to make healthcare more affordable, SB167 has generated discussion regarding concerns from both health insurance companies and advocacy groups. Insurers may argue that the requirement to credit these expenses could complicate their administrative processes and ultimately lead to increased premiums for consumers. Additionally, there are worries about how effectively this bill will be implemented without creating loopholes that might allow covered individuals to abuse the system. Potential contention points also include the requirements for proof of payment, which some suggest could be burdensome and deter individuals from taking advantage of the new provisions.

Companion Bills

No companion bills found.

Previously Filed As

CO HB1012

Prescription Drug Benefit Information Transparency

CO HB1316

Changes to Definitions Monitoring of Prescription Drugs

CO HB1004

Sale of Tax Credits

CO HB1296

Tax Expenditure Adjustment

CO SB071

Prohibit Restrictions on 340B Drugs

CO SB289

Creation of a Drug Donation Program

CO SB301

Remove Authorization Requirement Adjust Chronic Prescription

CO SB006

Tax Credit for Health Savings Accounts

CO SB319

Modification Higher Education Expenses Income Tax Incentive

CO SB307

Decarbonization Tax Credits Administration Cash Fund

Similar Bills

FL S1166

Insurer Disclosures on Prescription Drug Coverage

CA AB1320

California Affordable Drug Manufacturing Act of 2020: opioid antagonists.

CA SB1089

Preventive Treatment Health Care Act.

AK SB276

Contraceptives: Insurance Coverage

CA SB1199

Prescription drug cost sharing.

CA AB910

Pharmacy benefit management.

FL S0854

Small Independent Special Fire Control Districts

FL S1158

Drug Prices and Coverage